Forward Science shares research about SalivaMax's efficacy
Forward Science recently partnered with a regional cancer center in Colorado to conduct a study for the use of SalivaMAX for the mitigation of oral mucositis.
Forward Science recently partnered with a regional cancer center in Colorado to conduct a study for the use of SalivaMax for the mitigation of oral mucositis. The retrospective study published in the Journal of Cancer Therapy demonstrated that the powdered supersaturated calcium phosphate rinse was a statistically significant more effective method of oral mucositis mitigation than the standard of care.
SalivaMax, which is manufactured by Forward Science, is an FDA-cleared prescription rinse that is indicated for both xerostomia and mucositis. Forward Science wanted the study to quantify the success of SalivaMAX for use in oncology.
With the advancements in oncology drugs over the past decade, new discoveries have eliminated some of the most common side effect such as nausea with chemotherapy. Unfortunately, oral mucositis is now being one of the most common side effects for oncology treatments. Oral mucositis has a significantly negative impact on a patients' quality of life and pain as well as their treatment costs.
An online version of the study can be viewed here.
The control, a soda / salt rinse, was compared to a powered supersaturated calcium phosphate rinse (SSCPR) (SalivaMax). One of the oncology clinicians during the study reported, "Not only has SalivaMax reduced the severity of oral mucositis, it has pushed back the onset by almost one week."
Brian Pikkula, PhD, president and co-founder of Forward Science, said, "We hope this data will help turn the tide so that SalivaMax is recognized as the standard of care in oncology centers."
Forward Science, which is based in Houston, also manufactures OralID, an oral cancer screening device. To learn more about Forward Science, please visit forwardscience.com.